Article ID Journal Published Year Pages File Type
5695457 Gynecologic Oncology 2017 4 Pages PDF
Abstract

•Bevacizumab has significant activity in recurrent low-grade serous carcinoma.•A significant proportion of women discontinued bevacizumab due to adverse events.•Based on this large, retrospective experience, a prospective clinical trial is warranted.

ObjectiveThe aim of this study was to evaluate the activity of bevacizumab in a cohort of women with recurrent low-grade serous carcinoma of the ovary or peritoneum.MethodsThis single-institution retrospective study assessed all patients at MD Anderson Cancer Center with recurrent low-grade serous ovarian or peritoneal cancer who received bevacizumab from 2007 to 2016. Study endpoints included best response, median progression-free survival, median overall survival, and toxicity.ResultsForty patients received 45 separate “patient-regimens.” Most received bevacizumab in combination with chemotherapy. Complete response (CR) was seen in 7.5%, while 40% had partial responses (PR) and 30% achieved stable disease (SD). Disease progression occurred in nine patients (22.5%). Overall response rate (CR + PR) to bevacizumab-containing regimens was 47.5%. Clinical benefit (CR + PR + SD) was seen in 77.5% of patients. Median progression free survival was 10.2 months (95% CI 7.9, 12.4). Median overall survival was 34.6 months (95% CI 29.5, 39.7). Fifteen patients discontinued bevacizumab related to toxicity.ConclusionsBevacizumab, most often in combination with chemotherapy, has activity in recurrent low-grade ovarian cancer and should be considered a treatment option for these patients. Further investigation into the most effective chemotherapeutic agent in combination with bevacizumab is warranted.

Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Authors
, , , , , ,